A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Inclusion Criteria: * Adult patients, \>/= 18 years of age * Histologically or cytologically documented, inoperable, locally advanced, recurrent or metastatic (Stage IIIB or Stage IV) lung adenocarcinoma * Non-small cell lung cancer with an EGFR activating mutation * Patients must have evidence of disease, but measurable disease is not mandatory * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Adequate renal and liver function Exclusion Criteria: * Prior chemotherapy or other systemic anti-cancer treatment. Neoadjuvant/adjuvant chemotherapy is allowed if completed within 6 months prior to enrolment. Prior radiochemotherapy is allowed if completed more than 6 months before start of study treatment * Prior therapy with systemic anti-tumour therapy with HER1/EGFR inhibitors * Any other malignancies within 5 years, except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin carcinoma * Brain metastasis or spinal cord compression not yet definitely treated with surgery and/or radiation * Patients unable to take oral medication or requiring intravenous alimentation, with prior surgical procedures affecting absorption or active peptic ulcer disease * Any significant ophthalmologic abnormality, especially those likely to increase the risk of corneal epithelial lesions; the use of contact lenses is not recommended during the study * Pregnant or breast-feeding women